| 279 |
Counselling for regular follow-up during the treatment |
02/06/2024 |
DR-TB and PMDT |
| 280 |
Counselling for TB treatment initiation |
02/06/2024 |
DR-TB and PMDT |
| 354 |
Burden of DR-TB in India |
02/06/2024 |
DR-TB and PMDT |
| 625 |
Adverse Drug Reactions(ADRs) to First Line Treatment |
02/06/2024 |
DR-TB and PMDT |
| 626 |
Adverse Drug Reactions(ADRs) to Second Line Treatment |
02/06/2024 |
DR-TB and PMDT |
| 629 |
Screening for DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 630 |
DR-TB Treatment Regimens |
02/06/2024 |
DR-TB and PMDT |
| 729 |
Integrated DR-TB Algorithm |
02/06/2024 |
DR-TB and PMDT |
| 745 |
Pharmacovigilance in NTEP |
02/06/2024 |
DR-TB and PMDT |
| 749 |
Prevention of Drug Resistance |
02/06/2024 |
DR-TB and PMDT |
| 771 |
Types of Drug Resistance Tuberculosis -DRTB |
02/06/2024 |
DR-TB and PMDT |
| 977 |
List of Drugs that can be Used Safely or Avoided along with Bedaquiline |
02/06/2024 |
DR-TB and PMDT |
| 979 |
Use of Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen in Special Situations |
02/06/2024 |
DR-TB and PMDT |
| 983 |
Eligibility Criteria for Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 984 |
Treatment Extension in Isoniazid [H] Mono/Poly DR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 988 |
Management of DR-TB ADR: Diarrhoea and/or Flatulence |
02/06/2024 |
DR-TB and PMDT |
| 999 |
Management of DR-TB Patients: Lost to Follow-up |
02/06/2024 |
DR-TB and PMDT |
| 1062 |
Causes for Drug-resistant Tuberculosis |
02/06/2024 |
DR-TB and PMDT |
| 1014 |
Guidelines for Issuing Bedaquiline and Delamanid to the Patient |
02/06/2024 |
DR-TB and PMDT |
| 1019 |
Drugs Used in the Management of Adverse Events |
02/06/2024 |
DR-TB and PMDT |
| 1022 |
Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 1024 |
Eligibility Criteria for the Use of Delamanid [Dlm] in MDR/RR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 1037 |
Pre-treatment Evaluation [PTE] of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1039 |
Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up |
02/06/2024 |
DR-TB and PMDT |
| 1040 |
DR-TB Treatment in Pregnancy: General Considerations |
02/06/2024 |
DR-TB and PMDT |
| 1041 |
Immune Reconstitution Inflammatory Syndrome [IRIS] |
02/06/2024 |
DR-TB and PMDT |
| 1042 |
Common or Relevant Adverse Effects of DR-TB Therapy |
02/06/2024 |
DR-TB and PMDT |
| 1043 |
Management of QT Prolongation by Grade of Severity of ADR |
02/06/2024 |
DR-TB and PMDT |
| 1044 |
Management of Prolonged QTcF During Treatment with Shorter/Longer Oral MDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1045 |
State PMDT Committee: Terms of Reference [ToR] |
02/06/2024 |
DR-TB and PMDT |
